Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Agenus cancer vaccine extends survival of GBM patients.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(2):252-3. No abstract available.

PMID:
24963517
2.

Dendritic cell immunotherapy for glioblastoma.

Polyzoidis S, Ashkan K.

Expert Rev Anticancer Ther. 2014 Jul;14(7):761-3. doi: 10.1586/14737140.2014.921571. Epub 2014 May 21.

PMID:
24850137
3.

Dendritic cell vaccines to combat glioblastoma.

Wheeler CJ.

Expert Rev Neurother. 2010 Apr;10(4):483-6. doi: 10.1586/ern.10.26. No abstract available.

PMID:
20367199
4.

Promising vaccines for treating glioblastoma.

Swartz AM, Shen SH, Salgado MA, Congdon KL, Sanchez-Perez L.

Expert Opin Biol Ther. 2018 Nov;18(11):1159-1170. doi: 10.1080/14712598.2018.1531846. Epub 2018 Oct 15. Review.

PMID:
30281978
5.

Agenus’ brain cancer vaccine doubles survival rate in GBM patients.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(8):2139-40. doi: 10.4161/hv.36804. No abstract available.

6.

Immunotherapy in human glioblastoma.

Szabo AT, Carpentier AF.

Rev Neurol (Paris). 2011 Oct;167(10):668-72. doi: 10.1016/j.neurol.2011.07.002. Epub 2011 Aug 31. Review.

PMID:
21885075
7.

Immunotherapy with tumor vaccines for the treatment of malignant gliomas.

Ajay D, Sanchez-Perez L, Choi BD, De Leon G, Sampson JH.

Curr Drug Discov Technol. 2012 Dec;9(4):237-55. Review.

PMID:
22339070
8.

Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.

Okonogi N, Shirai K, Oike T, Murata K, Noda SE, Suzuki Y, Nakano T.

Anticancer Res. 2015 Mar;35(3):1229-35. Review.

PMID:
25750269
9.

Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.

Swartz AM, Li QJ, Sampson JH.

Immunotherapy. 2014;6(6):679-90. doi: 10.2217/imt.14.21. Review.

10.

Advances in Immunotherapy for Glioblastoma Multiforme.

Huang B, Zhang H, Gu L, Ye B, Jian Z, Stary C, Xiong X.

J Immunol Res. 2017;2017:3597613. doi: 10.1155/2017/3597613. Epub 2017 Feb 19. Review.

11.

Vaccine-based immunotherapy for glioblastoma.

Thomas AA, Fisher JL, Ernstoff MS, Fadul CE.

CNS Oncol. 2013 Jul;2(4):331-49. doi: 10.2217/cns.13.29. Review.

12.

Immunotherapy trials for glioblastoma multiforme: promise and pitfalls.

Yong RL, Lonser RR.

World Neurosurg. 2012 May-Jun;77(5-6):636-8. doi: 10.1016/j.wneu.2011.10.010. Epub 2011 Nov 1. No abstract available.

PMID:
22120230
13.

The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.

Heimberger AB, Sampson JH.

Expert Opin Biol Ther. 2009 Aug;9(8):1087-98. doi: 10.1517/14712590903124346. Review.

14.

Hope and challenges for dendritic cell-based vaccine therapy for glioblastoma.

Nakano I, Chiocca EA.

World Neurosurg. 2012 May-Jun;77(5-6):633-5. doi: 10.1016/j.wneu.2011.10.012. Epub 2011 Nov 1. No abstract available.

PMID:
22120228
15.

Vaccine for aggressive brain tumors may prolong survival.

[No authors listed]

Health News. 2004 Dec;10(12):7. No abstract available.

PMID:
15645564
16.

Current vaccine trials in glioblastoma: a review.

Xu LW, Chow KK, Lim M, Li G.

J Immunol Res. 2014;2014:796856. doi: 10.1155/2014/796856. Epub 2014 Apr 3. Review.

17.

[II. Autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma].

Maruyama T, Muragaki Y, Ishikawa E, Nitta M, Saito T, Ohno T, Iseki H, Okada Y.

Gan To Kagaku Ryoho. 2015 Jun;42(6):683-6. Japanese. No abstract available.

PMID:
26242005
18.

Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.

Del Vecchio CA, Li G, Wong AJ.

Expert Rev Vaccines. 2012 Feb;11(2):133-44. doi: 10.1586/erv.11.177. Review.

PMID:
22309662
19.

Heat shock protein vaccines against glioblastoma: from bench to bedside.

Ampie L, Choy W, Lamano JB, Fakurnejad S, Bloch O, Parsa AT.

J Neurooncol. 2015 Jul;123(3):441-8. doi: 10.1007/s11060-015-1837-7. Epub 2015 Jun 21. Review.

20.

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.

Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin J, Van Calenbergh F, Menten J, Clement P, Debiec-Rychter M, De Vleeschouwer S.

Cancer Immunol Immunother. 2012 Nov;61(11):2033-44. doi: 10.1007/s00262-012-1261-1. Epub 2012 Apr 22.

PMID:
22527250

Supplemental Content

Support Center